Galecto files updated corporate presentation for January 2022 investor meetings

Damora Therapeutics, Inc.

Presentation titled 'First-in-class small-molecule anti-fibrotic and anti-cancer agents'.
Filed under Regulation FD; presentation dated January 2022.
No specific new financial or pipeline details disclosed in the filing.

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-000413

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.